Synergistic anticancer mechanisms of curcumol and paclitaxel in triple-negative breast cancer treatment may involve down-regulating ZBTB7A expression via the NF-B signaling pathway [PDF]
Iranian Journal of Basic Medical Sciences, 2022 Objective(s): This study aimed to verify whether curcumol combined with paclitaxel exerted synergistic antiproliferative and proapoptotic effects in MDA-MB-231 mammary cancer cells.Materials and Methods: The effects of different concentrations of CC, PTX,
Anyun Mao +3 more
doaj +1 more source
Establishment of A Novel Paclitaxel-Resistant Triple-Negative Breast Cancer Cell Line
Journal of Health Science and Medical Research (JHSMR), 2023 Objective: Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, and is associated with poor prognosis. Paclitaxel, a microtubule-binding agent, and chemotherapeutic agent, has been widely used in the management of
Thanaporn Khunpitak, Pasarat Khongkow
doaj +1 more source
Advances in Treatment of Triple Negative Breast Cancer
Zhongliu Fangzhi Yanjiu, 2022 TNBC is a special type of breast cancer with strong aggressiveness and poor prognosis. Chemotherapy is still the main treatment for TNBC, due to poor efficacy of endocrine therapy and targeted therapy. However, TNBC is a kind of heterogeneous disease, so
KANG Yikun, YUAN Peng
doaj +1 more source
Filamin-A expression in triple-negative breast cancer and its clinical significance
Biotechnology & Biotechnological Equipment, 2021 The quest for discovering novel biomarkers of triple-negative breast cancers (TNBCs) is ongoing. By lacking expression of hormonal receptors, this aggressive subtype of breast cancer presents a clinical dilemma with early recurrence, metastases and poor ...
Abderrahman Ouban
doaj +1 more source
Establishing the promising role of novel combination of triple therapeutics delivery using polymeric nanoparticles for Triple negative breast cancer therapy [PDF]
BioImpacts, 2021 Introduction: Triple-negative breast cancer (TNBC) is a lethal tumor with an advanced degree of metastasis and poor survivability as compared to other subtypes of breast cancer.
Ranjita Misra +3 more
doaj +1 more source
Reprogramming of VEGF-mediated extracellular matrix changes through autocrine signaling
Cancer Biology & Therapy, 2023 Vascular endothelial growth factor (VEGF) plays key roles in angiogenesis, vasculogenesis, and wound healing. In cancers, including triple negative breast cancer (TNBC), VEGF has been associated with increased invasion and metastasis, processes that ...
Eibhlin Goggins +6 more
doaj +1 more source
Disulfiram/Copper Induce Ferroptosis in Triple-Negative Breast Cancer Cell Line MDA-MB-231
Frontiers in Bioscience-Landmark, 2023 Background: The complex formed by disulfiram (DSF) and copper (Cu) is safe and effective for the prevention and treatment of triple-negative breast cancer (TNBC). Although previous studies have shown that DSF/Cu induces ferroptosis, the mechanism remains
Meiran Chu +8 more
doaj +1 more source
BBOX1 promotes triple-negative breast cancer progression by controlling IP3R3 stability
Molecular & Cellular Oncology, 2020 Limited therapeutic options impede the clinical outcome of triple-negative breast cancer (TNBC). Our recent study uncovered a novel signaling pathway implicating gamma-butyrobetaine hydroxylase 1 (BBOX1) in the control of cell growth in TNBC, via ...
Chengheng Liao, Qing Zhang
doaj +1 more source
Rarest of the rare-male triple negative breast cancer
Journal of Dr. NTR University of Health Sciences, 2022 Breast cancer in males is rare. Luminal A is the predominant subtype in male breast cancer. Clinical data on triple negative breast cancer in male patients is sparse. This case report will add to the literature on male breast cancers. This is a rare case
Haneesha Polavarapu +4 more
doaj +1 more source
Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo [PDF]
, 2016 Triple-negative breast cancer (TNBC) is the most lethal form of breast cancer. Lacking effective therapeutic options hinders treatment of TNBC. Here, we show that bepridil (BPD) and trifluoperazine (TFP), which are FDA-approved drugs for treatment of ...
Berek, Jonathan S +5 more
core +2 more sources